DSS Subsidiary Impact Biomedical Reports Positive Test Results For 3FDB DEET Booster Technology - DSS (AMEX:DSS)

Document Security Systems, Inc. DSS, subsidiary Impact Biomedical, Inc, along with its scientific research partner Global Research and Discovery Group Sciences, GRDG, announced encouraging results from clinical tests of its 3FDB (DEET Booster) technology.
The results suggest that 3FDB can boost the effectiveness of mosquito repellants, specifically DEET. Working with an independent lab, GRDG conducted three tests involving the mosquito (Aedes aegypti).
Daryl Thompson, Director of Scientific Initiatives at GRDG, stated, "These tests represent an important development in addressing mosquito-borne diseases and could signal a new frontier of protection strategies."
Recently, Impact Biomedical and GRDG received a U.S. Patent for 3FDB (US 10,966,424), a Functional Fragrance Formulation, which increases the current mosquito repellants' effectiveness through light and a fragrant compound derived from botanical oils.
Price Action: DSS shares are trading lower by 3.16% at $1.2686 on the last check Monday.